Adenosine receptor agonists: from basic medicinal chemistry to clinical development

Bibliography

• DRURY AN, SZENT-GYORGYI A: The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. Physic] (1929) 68:213–237.
   Google Scholar
• BURNSTOCK G: A basis for distinguishing two types of purinergic receptors. In: Cell membrane receptors for drugs and hormones. Boats L, Straub RW (Eds), Raven, New York (1978):107–118.
   Google Scholar
• FREDHOLM BB, ABBRACCHIO MP, BURNSTOCK G et al.: VI: Nomenclature and classification of purinoceptors. Pharmacol Rey (1994) 46:143–156.
   PubMed Web of Science ®Google Scholar
• TELLER DC, OKADA T, BEHNKE CA et al.: Advances in determination of a high-resolution three dimensional structure of rhodopsin, a model of G-protein coupled receptors. J. Mo/. Biol. (2001) 40:7761.
   Google Scholar
• MIRABET M, HERRERA C, CORDERO OJ et al.: Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. I Cell. Sci. (1999) 112:491–502.
   Web of Science ®Google Scholar
• FREDHOLM BB, ARSLAN G, HALLDNER L et al.: Structure and function of adenosine receptors and their genes. Naunyn-SchrniedebergS Arch. Pharmacol (2000) 362:364–374.
   PubMed Web of Science ®Google Scholar
• DHALLA AK, SHRYOCK JC, SHREENIWAS R et al.: Pharmacology and therapeutic application of A1 adenosine receptor ligands. Carr: Topics Med. Chem. (2003) 3:369–385.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review by experts in the field.
   Google Scholar
• FREDHOLM BB, CUNHA RA, SVENNINGSSON P et al: Pharmacology of adenosine A2A receptors and therapeutic applications. Carr. Topics Med. Chem. (2003) 3:413–426.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review by experts in the field.
   Google Scholar
• FREDHOLM BB, IJZERMAN AP, JACOBSON KA et al.: International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 53:527–552.
   PubMed Web of Science ®Google Scholar
• PALZEWSKI K, KUMASAKA T, HORI T et al.: Crystal structure of rhodopsin: a G-protein coupled receptor. Science (2000) 289:739-745 BONDAVALLI F, BOTTA M, BRUNO 0 et al.: Synthesis, molecular modeling studies,and pharmacological activity of selective A1 receptor antagonists. Med. Chem. (2002) 45:4875–4887.
   Web of Science ®Google Scholar
• GAO ZG, CHEN A, BARAK D et al: Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J. Biol. Chem. (2002) 277:19056–19063.
   PubMed Web of Science ®Google Scholar
• GAO ZG, JIANG Q, JACOBSON KA, JIZERMAN AP: Site-directed mutagenesis studies of human A2A adenosine receptors. Biochem. Pharmacol (2000) 60:661–668.
   PubMed Web of Science ®Google Scholar
• JIZERMAN AP, VON FRIJTAG DRABBE KONZEL JK, KIM J et al.: Site-directed mutagenesis of the human adenosine A2A-receptor. Critical involvement of G1u13 in agonist recognition. Eur. Pharmacol (1996) 310:269–272.
   PubMed Web of Science ®Google Scholar
• JIANG Q, LEE BX, GLASHOFER M et al.: Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G-protein coupled receptors. Med.Chem (1997) 40:2588–2595.
   Web of Science ®Google Scholar
• KIM J, WESS J, VAN RHEE AM et al.: Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2A adenosine receptor. J. Biol. Chem. (1995) 270:13987–13997.
   PubMed Web of Science ®Google Scholar
• MOLLER CE: Al-Adenosine receptor antagonists. Expert Opin. Ther. Patents (1997) 7:419–440.
   Web of Science ®Google Scholar
• RIVKEES SA, BARBHAIYA H, LIZERMAN AP: Identification of the adenine binding site of the human A1 adenosine receptor." Biol. Chem (1999) 274:3617–3621.
   PubMed Web of Science ®Google Scholar
• TUCKER AL, ROBEVA AS, TAYLOR HE et al.: A1 Adenosine receptors.' Biol. Chem. (1994) 269:27900–27906.
   Web of Science ®Google Scholar
• BRUNS RF: Adenosine receptor activation in human fibroblasts: Nucleoside agonists and antagonists. Can. I Physiol Pharmacol (1980) 58:673–691.
   PubMed Web of Science ®Google Scholar
• BALLESTEROS JA, WEINSTEIN H: Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci (1995) 25:366–428.
   Google Scholar
• BRUNS RG, LU GG, PUGSLEY TA: Characterization of the A2 adenosine receptor labeled by PH]NECA in rat striatal membranes. Ma Pharmacol (1986) 29:331–346.
   PubMed Web of Science ®Google Scholar
• KLOTZ KN: Adenosine receptors and their ligands. Naunyn-Schmiedeberg's Arch. Pharmacol (2000) 362:382–391.
   Google Scholar
• MOLLER CE: Adenosine receptor ligands - recent developments. Part I. Agonists. Carr. Med. Chem. (2000) 7:1269–1288.
   PubMed Web of Science ®Google Scholar
• LOHSE MJ, KLOTZ KN, LINDENBORN-FOTINOS J et al: 8-Cyclopenty1-1,3-dipropylxanthine (DPCPX) - a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn-SchrniedebergS Arch. Pharmacol (1987) 336:204–210.
   PubMed Web of Science ®Google Scholar
• ZOCCHI C, ONGINI E, FERRARA S et al.: Binding of the radioligand PHI5CH58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br. .1. Pharinacol. (1996) 117:1381–1386.
   Google Scholar
• MOLLER CE, MAURINSH J, SAUER R: Binding of PH]MSX-2 (3-(3-hydroxypropyl) - 7-methyl 8 m methoxystyry1)-1-propargylxanthine) to rat striatal membranes - a new selective antagonist radioligand for A2A adenosine receptors. Eur. Pharm. ScL (2000) 10:259–265.
   PubMed Web of Science ®Google Scholar
• ALEXANDER SP, MILLNS PJ: [3H]ZM241385 - an antagonist radioligand for adenosine A2A receptors in brain. Eur.j Pharmacol (2001) 411:205–210.
   PubMed Web of Science ®Google Scholar
• JI X, KIM YC, AHERN DG et al: [3H]MRS 1754, a selective antagonist radioligand for A2B adenosine receptors. Biochem. Pharmacol (2001) 61:657–663.
   PubMed Web of Science ®Google Scholar
• DIEKMANN M, BERTARELLI D, MOLLER CE et al.: unpublished.
   Google Scholar
• VARANI K, MERIGHI S, GESSI S et al: [3H]lARE 3008E20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol (2000) 57:968–975.
   PubMed Web of Science ®Google Scholar
• MOLLER CE, DIEKMANN M, THORAND M et al.: PH]8-Ethy1-4-methy1-2-phenyl-(8A-4,5,7,8-tetrahydro-1H-imidazo [2,1-4 purin-5-one ( PHIPSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors. Bioorg. Med. Chem. Lett. (2002) 12:501–503.
   PubMed Web of Science ®Google Scholar
• MURPHREE LJ, MARSHALL MA, RIEGER JM et al.: Human A2A adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing G34. Mol Pharm. (2002), 61:455–462.
   Web of Science ®Google Scholar
• KLOTZ KN, KEIL R, ZIMMER FJ et al.: Guanine nucleotide effects on 8-cyclopentyl-1,3- [3H]dipropylxanthine binding to membrane-bound and solubilized A1 adenosine receptors of rat brain. J. Neurochem. (1990) 54:1988–1994.
   PubMed Web of Science ®Google Scholar
• EHLERT FJ: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol (1988) 33:187–194.
   PubMed Web of Science ®Google Scholar
• VAN DER WENDEN EM, CAENIELLI M, ROELEN HCPF et al: 5'-Substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor. I Med. Chem. (1998) 41:102–108.
   PubMed Web of Science ®Google Scholar
• SHRYOCK JC, OZECK MJ, BELARDINELLI L: Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol (1998) 53:886–893.
   PubMed Web of Science ®Google Scholar
• LORENZEN A, GUERRA L, VOGT H et al.: Interaction of full and partial agonists of the A1 adenosine receptor with receptor/ G protein complexes in rat brain membranes. Ma Pharmacol (1996) 49:915–926.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA: Adenosine receptor agonists. Expert Opin. Then Patents (2002) 12:489–501.
   Web of Science ®Google Scholar
• ••Excellent and unique overviewincluding recently patented novel structures of AR agonists.
   Google Scholar
• MOLLER CE, STEIN B: Adenosine receptor antagonists: Structure and potential therapeutic applications. Current Pharm. Design (1996) 2:501–530.
   Web of Science ®Google Scholar
• FREDHOLM BB, IRENIUS E, KULL B et al.: Comparison of potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol (2001) 61:443–448.
   PubMed Web of Science ®Google Scholar
• POULSEN SA, QUINN RJ: Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. (1998) 6:619–641.
   PubMed Web of Science ®Google Scholar
• RIBEIRO JA, SEBASTIAO AM: Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor. Frog. Neurobiol (1986) 26:179–209.
   Google Scholar
• MOLLER CE: Medicinal chemistry of adenosine A3 receptor ligands. Carr: Topics Med. Chem. (2003) 3:445–462.
   PubMed Web of Science ®Google Scholar
• RODEN DM.: Antiarrhythmic drugs. In: Goodman & Gilman's The pharmacological bash of therapeutics. (9th Edition), Goodman LS, Limbird LE, Milinoff PB, Ruddon RW, Goodman Gilman A, Hardman JG (Eds), McGraw-Hill, USA (1995):858–859.
   Google Scholar
• LEESAR MA, STODDARD M, AHMED, M et al.: Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation (1997) 95:2500–2507.
   PubMed Web of Science ®Google Scholar
• WITTWER LK, MUHE MD: Adenosine for the treatment of PSVT in the prehospital arena: efficacy of an initial 6 mg dosing regimen. Prehospital Disaster Med. (1997) 12:237–239.
   PubMedGoogle Scholar
• KITAKAZE M, HORT M: Adenosine therapy: a new approach to chronic heart failure. Expert Opin. Investig. Drugs (2000) 9:2519–2535.
   PubMed Web of Science ®Google Scholar
• MARX D, EZEAMUZIE CI, NIEBER K et al.: Therapy of bronchial asthma with adenosine receptor agonists or antagonists. Drug News Paved-. (2001) 14:89–100.
   PubMed Web of Science ®Google Scholar
• FORSYTHE P, ENNI M: Adenosine, mast cells and asthma. Inhanon. Res. (1999) 48:301–307.
   PubMed Web of Science ®Google Scholar
• INSCHO EW: Modulation of renal microvascular function by adenosine. Am.' Physiol. Regal. Integr: Comp. Plysiol. (2003) 285:R23–R25.
   PubMed Web of Science ®Google Scholar
• LERMAN BB, BELARDINELLI L: Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation (1991) 83:1499–1509.
   PubMed Web of Science ®Google Scholar
• DIMARCO JP, SELLERS TD, LERMAN BB et al: Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. Am. Coll. Cardiol. (1985) 6:417–425.
   PubMed Web of Science ®Google Scholar
• LEHEL S, HORVATH G, MIKECZ P et al.: Synthesis of 5'-N-(2- PH Fluor° ethyl) carboxamidoadenosine: a promising tracer for investigation of adenosine receptor system by PET technique. I Labelled Cpd. Radiopliarm (2000) 43:807–815.
   Web of Science ®Google Scholar
• SAWCHUK RI, YANG Z: Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Advanced Drug Delivery Rev (1999) 39:5–31.
   PubMed Web of Science ®Google Scholar
• MERIGHI S, VARANI K, GESSI S et al: Binding thermodynamics at the human A3 adenosine receptor. Biocliem. Pliarmacol. (2002) 63:157–161.
   PubMed Web of Science ®Google Scholar
• DE ZWART M, LINK R, VON FRIJTAG DRABBE KONZEL JK et al.: A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. Nucleosides Nucleotides (1998) 17:969–985.
   PubMed Web of Science ®Google Scholar
• SIDDIQI SM, JACOBSON KA, ESKER JL et al.: Search for new purine-and ribose-modified adenosine analogs as selective agonists and antagonists at adenosine receptors. j. Med. Chem. (1995) 38:1174–1188.
   PubMed Web of Science ®Google Scholar
• VITTORI S, LORENZEN A, STANNEK C et al: N-Cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor. Med. Chem. (2000) 43:250–260.
   Web of Science ®Google Scholar
• WANNER MJ, VON FRIJTAG DRABBE KONZEL JK, IJZERMAN AP et al.: 2-Nitro analogues of adenosine and 1-deazaadenosine: Synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes. Bioorg. Med. Chem. Lett. (2000) 10:2141–2144.
   PubMed Web of Science ®Google Scholar
• KNUTSEN LJ, LAU J, PETERSEN H et al.: N-Substituted adenosine as novel neuroprotective A1 agonists with diminished hypotensive effects. j. Med. Chem. (1999) 42:3463–3477.
   PubMed Web of Science ®Google Scholar
• LOUTTIT JB, HUNT AAE, MAXWELL MP et al.: The time course of cardioprotection induced by GR79236, a selective adenosine Al-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. Cardiovasc. Pliarmacol. (1999) 33:285–291.
   PubMed Web of Science ®Google Scholar
• BAXTER GE HALE SL, MIKI T et al.: Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc. Drug Ther: (2000) 14:607–614.
   PubMed Web of Science ®Google Scholar
• TEOH LK, GRANT R, HULF JA et al.: The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc. Res. (2002) 53:175–180.
   PubMed Web of Science ®Google Scholar
• KELION AD, WEBB TP, GARDNER MA et al.: Does a selective adenosine A1 receptor agonist protect against exercise induced ischemia in patients with coronary artery disease? Heart (2002) 87:115–120.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, HOSKIN KL, STORER RJ et al.: Adenosine A1 receptor agonist inhibit trigeminovascular nociceptive transmission. Brain (2002) 125:1392–1401.
   PubMed Web of Science ®Google Scholar
• GRIFFIN NJ, KOWACS F, LIBRI V et al: Effect of the adenosine A1 receptor agonist on trigeminal nociception with blink reflex recordings in healthy human subjects. Ceplialalgia (2003) 23:287–292.
   PubMed Web of Science ®Google Scholar
• HONEY AC, BLAND-WARD PA, CONNOR HE: Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. Ceplialalgia (2002) 22:260–264.
   PubMed Web of Science ®Google Scholar
• PIOT O, CHUVEL C, LAZARUS A et al.: Effects of a selective Al-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation. Pacing Clin. Electrophysiol. (1998) 21:2459–2464.
   PubMed Web of Science ®Google Scholar
• KLOTZ KN, HESSLING J, HEGLER J et al.: Comparative pharmacology of human adenosine receptor subtypes - characterization of stably tranfected receptors in CHO cells. Naunyn-Scbmiedeberg's Arch. Pliarmacol. (1998) 357:1–9.
   Google Scholar
• FRANCHETTI P, CAPPELLACCI L, MARCHETTI S et al.: 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.Med. Chem. (1998) 41:1708–1715.
   Web of Science ®Google Scholar
• PRASHAD M, PRASAD K, REPIC 0: A practical synthesis of SDZ WAG994 by selective methylation of N6-cyclohexyladenosine. Synthetic Commun. (1996) 26:3967–3977.
   Web of Science ®Google Scholar
• HUTCHINSON SA, BAKER SP, SCAMMELLS PJ: New 2,N6-disubstituted adenosines: potent and selective A1 adenosine receptor agonists. Bioorg. Med. Chem. (2002) 10:1115–1122.
   PubMed Web of Science ®Google Scholar
• PEAKMAN MC, HILL SJ: Adenosine Am receptor mediated cyclic AMP accumulation in primary rat astrocytes. Br. Pliarmacol. (1994) 111:191–198.
   PubMed Web of Science ®Google Scholar
• ZHOU Q, LI C, OLAH ME et al.: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1992) 89:7432–7436.
   PubMed Web of Science ®Google Scholar
• KNUTSEN US, LAU J, SHEARDOWN MJ et al: The synthesis and biochemical evalution of new A1 selective adenosine receptor agonists containing 6-hydrazino purine moieties. Bioorg. Med. Chem. Lett. (1993) 3:2661–2666.
   Web of Science ®Google Scholar
• HA SB, JACOBSON KA, NAIR V et al.: New base-altered adenosine analogues: synthesis and affinity at adenosine A1 and A2A receptors. Bioorg. Med. Chem. Lett. (1997) 7:3085–3090.
   PubMed Web of Science ®Google Scholar
• BEUKERS MW, WANNER MJ, VON FRIJTAG DRABBE KONZEL JK et al.: N6-Cyclopentyl 2 (3 phenylaminocarbonyltriazene-1-yfladenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. I Med. Chem. (2003) 46:1492–1503.
   Web of Science ®Google Scholar
• JACOBSON KA, JI XD, LI AH et al: Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. j. Med. Chem. (2000) 43:2196–2203.
   PubMed Web of Science ®Google Scholar
• CAPPELACCI L, BARBONI G, PALMIERI M et al: Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of r-C-methyl adenosine analogues. j Med. Chem. (2002) 45:1196–1202.
   PubMed Web of Science ®Google Scholar
• SMITS GJ, MCVEY M, COX BF et al: Cardioprotective effects of the novel adenosine A11A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J. Pharm. Exp. Ther. (1998) 286:611–618.
   PubMed Web of Science ®Google Scholar
• CLARK KL, MERKEL L, ZANNIKOS P et al.: AMP 579, a novel adenosine agonist for the treatment of acute myocardial infarction. Cardiovasc. Drug Rev (2000) 18:183–210.
   Google Scholar
• NAKAMURA M, ZHAO ZQ, CLARK KL et al.: A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium. Eur: J Pharmacol (2000) 397:197–205.
   PubMed Web of Science ®Google Scholar
• BUDDE JM, VELEZ DA, ZHAO Z et al: Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc. Res. (2000) 47:294–305.
   PubMed Web of Science ®Google Scholar
• XU Z, DOWNEY JM, COHEN MV: AMP 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. Cardiovasc. Pharmacol (2001) 38:474–481.
   PubMed Web of Science ®Google Scholar
• KOPECKY SL, AVILES RJ, BELL MR et al.: A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AMP579 Delivery for Myocardial Infarct REduction) study. Am. Heart J. (2003) 146:146–152.
   PubMed Web of Science ®Google Scholar
• MOLLER CE: Al adenosine receptors and their ligands: overview and recent developments. Farmaco (2001) 56:77–80.
   PubMedGoogle Scholar
• DE LIGT RA, IJZERMAN AP: Instrinsic activity at adenosine A1 receptors: partial and inverse agonism. Curr: Pharm. Design (2002) 8:2333–2344.
   PubMed Web of Science ®Google Scholar
• VAN DER WENDEN EM, HARTOG-WITTE HR, ROELEN HCPF et al.: 8-Substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor. Eur: .1 Pharmacol Mol Pharmacol Section (1995) 290:189–199.
   Google Scholar
• MATHOT RA, VAN DER WENDEN EM, SOUDIJN W et al.: Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo. J. Pharmacol Exp. Ther: (1996) 279:1439–1446.
   PubMed Web of Science ®Google Scholar
• VAN SCHAICK E, MATHOT RA, GUBBENS-STIBBE JM et al.: 8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors M vivo. .1 Pharmacol Exp. Ther. (1997) 283:800–809.
   Google Scholar
• VAN SCHAICK EA, TUKKER HE, ROELEN H et al.: Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. Br. J Pharmacol (1998) 124:607–618.
   PubMed Web of Science ®Google Scholar
• VAN DER GRAAF PH, VAN SCHAICK EA, MATHOT RA: Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptor. J Pharmacol Exp. Ther. (1997) 283:809–816.
   PubMed Web of Science ®Google Scholar
• VAN TILBURG EW, VAN DER KLEIN PAM, VON FRIJTAG DRABBE KONZEL J et al.: 5'-0-Alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors. J Med. Chem. (2001) 44:2966–2975.
   PubMed Web of Science ®Google Scholar
• SONG Y, WU L, SHRYOCK JC et al.: Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation (2002) 105:118–123.
   PubMed Web of Science ®Google Scholar
• MOLLER CE, SCHUMACHER B, BRATTSTROM A et al: Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci. (2002) 71:1939–1949.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER B, SCHOLLE S, HOLZL J et al.: Lignans isolated from valerian: Identification and characterization of a novel olivil derivative with partial agonistic activity at A1 adenosine receptors. J Nat. Prod (2002) 65:1479–1485.
   PubMed Web of Science ®Google Scholar
• DENNIS D, RAATIKAINEN MJ, MARTENS JR et al.: Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation (1996) 94:2551–2559.
   PubMed Web of Science ®Google Scholar
• KOLLIAS-BAKER C, RUBLE J, DENNIS D et al.: Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac action of adenosine. Circulation Research (1994) 75:961–965.
   PubMed Web of Science ®Google Scholar
• KOUROUNAKIS A, VISSER C, DE GROOTE M et al.: Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl) [3-(trifluoromethyl)phenyl] - methanone (PD 81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem. Pharmacol (2001) 61:137–144.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, ZAID AN, LAMPRONTI I et al.: Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of Al-adenosine receptor. Bioorg. Med. Chem. Lett. (2000) 10:1953–1957.
   PubMed Web of Science ®Google Scholar
• BRUNS RF, FERGUS JH: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol (1990) 38:939–949.
   PubMed Web of Science ®Google Scholar
• BRUNS RE FERGUS JH, COUGHENOUR LL et al.: Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol (1990) 38:950–958.
   PubMed Web of Science ®Google Scholar
• VAN DER KLEIN PA, KOUROUNAKIS AP, IJZERMAN AP et al.: Allosteric modulation of the adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med. Chem. (1999) 42:3629–3635.
   PubMed Web of Science ®Google Scholar
• LUTJENS H, ZICKGRAF A, FIGLER H et al.: 2-Amino-3-benzoylthiophene allosteric enhancers of A1 adenosine agonist binding: new 3-, 4-, and 5-modifications. J Med. Chem. (2003) 46:1870–1877.
   PubMed Web of Science ®Google Scholar
• MOLLER CE, SCIOR T: Adenosine receptors and their modulators. Pharm. Acta Hely. (1993) 68:77–111.
   PubMedGoogle Scholar
• BELARDINELLI L, LERMAN BB: Electrophysiological basis for the use of adenosine in the diagnosis and treatment of cardiac arrhythmia. Br. Heart J. (1990) 63:3–4.
   PubMedGoogle Scholar
• SHRYOCK JC, BELARDINELLI L: Adenosine and adenosine receptors in the cardiovascular system: biochemistry physiology and pharmacology. Am. J. Cardiol (1997) 79:2–10.
   PubMed Web of Science ®Google Scholar
• GAO Z, ROSETE J, KOHLER G et al.: Negative chronotropic effect of CVT-510 in anaesthetized and awake rats. Drug Dev. Res. (2001) 52:424–430.
   Web of Science ®Google Scholar
• SORBERA LA, CASTANER J, MARTIN L et al.: Tecadenoson. Drugs Future (2002) 27:846–849.
   Web of Science ®Google Scholar
• CRISTALLI G, LAMBERTUCCI C, TAFFI S et al.: Medicinal chemistry of adenosine A2A receptor agonists. Curi: Top. Med. Chem. (2003) 3:387–401.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review by experts in the field.
   Google Scholar
• GAO Z, BAKER SP, LASLEY RD, MEYER S et al.: Novel short acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. Pharmacol. Exp. Ther. (2001) 298:209–218.
   PubMed Web of Science ®Google Scholar
• PALLE VP, ELIZEIN EO, GOTHE SA et al.: Structure-affinity relationships of the affinity of 2-pyrazoly1 adenosine analogues for the adenosine A2A receptor. Bioorg. Med. Chem. Lett. (2002) 12:2935–2939.
   PubMed Web of Science ®Google Scholar
• KOGI K, UCHIBORI T, AIHARA K et al.: Pharmacological profile of the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146) in the cardiovascular system. fpn. Pharmacol. (1991) 57:153–165.
   Web of Science ®Google Scholar
• GLOVER DK, RUIZ M, YANG JY et al: Pharmacological stress thallium scintigraphy with 2-cyclohexylmethylidenehydrazinoadenosine (VVRC-0470). Circulation (1996) 94:1726–1732.
   PubMed Web of Science ®Google Scholar
• TROCHU JN, ZHAO G, POST H et al.: Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. Cardiovasc. Pharmacol. (2003) 41: 132–139.
   Google Scholar
• HOGAN CJ, FANG GD, SCHELD WM et al.: Inhibiting the inflammatory response in joint sepsis. Arthroscopy (2001) 17: 311–315.
   Google Scholar
• OHTA A, SITKOVSKY M: Role of G protein-coupled receptors in downregulation of inflammation and protection from tissue damage. Nature (2001) 414:916–920.
   PubMed Web of Science ®Google Scholar
• ••Report on the anti-inflammatoryand tissue-protective role of A2A adenosine receptors.
   Google Scholar
• MARUMOTO R, YOSHIOKA Y, MIYASHITA 0 et al.: Synthesis and coronary vasodilating activity of 2-substituted adenosines. Chem. Pharm. Bull. (1975) 23:759–774.
   PubMed Web of Science ®Google Scholar
• THOMAS S: Using larvae therapy in modern wound management. J. Wound Care (1996) 5:60–69.
   PubMedGoogle Scholar
• SULLIVAN GW, RIEGER JM, SCHELD WM et al.: Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyladenosine A2A receptor agonists. Br. Pharmacol. (2001) 132:1017–1026.
   PubMed Web of Science ®Google Scholar
• GLOVER DK, RUIZ M, TAKEHANA K et al.: Pharmacological stress myocardial perfusion imaging with the potent and selective adenosine A2A receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation (2001) 104:1181–1187.
   PubMed Web of Science ®Google Scholar
• RIOU LM, RUIZ M, RIEGER JM et al.: Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A-A-receptor-mediated coronary vasodilation. film. Coll. Cardiol. (2002) 40:1687–1694.
   PubMed Web of Science ®Google Scholar
• CASSADA DC, TRIBBLE GC, YOUNG JS et al.: Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J. Trauma (2002) 53:225–229.
   PubMed Web of Science ®Google Scholar
• FISER SM, TRIBBLE CG, KAZA AK et al.: Adenosine A2A receptor activation decreases reperfusion injury associated with high-flow reperfusion.j. Thome. Cardiovasc. Sur& (2002) 124:973–978.
   PubMed Web of Science ®Google Scholar
• PEIRCE SM, SKALAK TC, RIEGER JM et al.: Selective A2A adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am. f. Physiol. Heart Circ. Physiol (2001) 281:H67–H74.
   PubMed Web of Science ®Google Scholar
• DALY JVV, PAD GETT WL: Agonist activity of 2- and 5'-substituted adenosine analogs and their M-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase. Biochem. Pharmacol. (1992) 43:1089–1093.
   PubMed Web of Science ®Google Scholar
• VAN GALEN PJM, VAN BERGEN AH, GALLO-RODRIGUEZ C et al.: A binding site model and structure-activity relationships for the rat A3 adenosine receptor. MM. Pharmacol. (1994) 45:1101–1111.
   PubMed Web of Science ®Google Scholar
• DALY JW, PADGETT WL, SECUNDA SI et al.: Structure-activity relationships for 2-substituted adenosines at Aland A2 adenosine receptors. Phamacology (1993) 46:91–100.
   Web of Science ®Google Scholar
• SALVATORE CA, JACOBSON MA, TAYLOR HE et al.: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Nati Acad. ScL USA (1993) 90: 10365–10369.
   Google Scholar
• LINDEN J, THAI T, FIGLER H et al.: Characterization of human A2B adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. (1999) 56:705–713.
   PubMed Web of Science ®Google Scholar
• VOLPINI R, CONSTANZI S, LAMBERTUCCI C et al.: N6-Alky1-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands. J. Med. Chem. (2002) 45:3271–3279.
   PubMed Web of Science ®Google Scholar
• DE ZWART M, DE GROOTE M, VAN DER KLEIN PAM et al.: Phenyl-substituted N6-phenyladenosines and N6-pheny1-5'-N-ethylcarboxamidoadenosines with high activity at human adenosine A2B receptors. Drug Dev. Res. (2000) 49:85–93.
   Web of Science ®Google Scholar
• DUBEY RK, GILLESPIE DG, ZAICHUAN M et al.: Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension (1998) 31:516–521.
   PubMed Web of Science ®Google Scholar
• PEYOT ML, GADEAU A-P, DANDRE F et al.: Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A2B purinoceptor. Circ. Res. (2000) 86:76–85.
   PubMed Web of Science ®Google Scholar
• MUNRO R, RESSNER R, STONE M et al.: Differential expression of adenosine A2A and A2B receptor subtypes on myeloid U937 and THP-1 cells: adenosine A2B receptor activation selectively stimulates cAMP formation and inhibition of TNF-a release in THP-1 cells. Drug Dev. Res. (1998) 44:41–47.
   Web of Science ®Google Scholar
• CLANCY JP, RUIZ FE, SORSCHER EJ: Adenosine and its nucleotides activate wild-type and R117H CFTR through an A2B receptor-coupled pathway. Cell. Physiol. (1999) 45:C361–C369.
   Google Scholar
• HANCOCK DL, COUPAR IM: Functional characterization of the adenosine receptor mediating inhibition of intestinal secretion. Br: J. Pharmacol. (1995) 114:152–166.
   PubMed Web of Science ®Google Scholar
• FEOKTISTOV I, WELLS JN, BIAGGIONI I: Adenosine A2B receptors as therapeutic targets. Drug Dev. Res. (1998) 45:198–206.
   Web of Science ®Google Scholar
• CHIANG PH, WU SN, TSAI EM et al.: Adenosine modulation of neurotransmission in penile erection. Br. J. Clio. Pharmacol. (1994) 38:357–362.
   PubMed Web of Science ®Google Scholar
• KIM HO, JI XD, SIDDIQI SM et al.: 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors..! Med. Chem. (1994) 37:3614–3621.
   Web of Science ®Google Scholar
• JACOBSON KA: Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol ScL (1998) 19:184–191.
   PubMed Web of Science ®Google Scholar
• VAN TILBURG EW, VON FRIJTAG DRABBE KONZEL J, DE GROOTE M et al.: N6,5'Disubstituted adenosine derivatives as partial agonists for the adenosine A3 receptor.' Med. Chem. (1999) 42:1393–1400.
   Web of Science ®Google Scholar
• GALLO-RODRIGUEZ C, JI X, MELMAN N et al.: Structure-activity relationships of N6-benzyladenosine-5'-uronamide as A3 adenosine agonists. Med. Chem. (1994) 37:636–646.
   Web of Science ®Google Scholar
• SIDDIQI SM, PEARLSTEIN RA, SANDERS LH et al.: Comparative molecular field analysis of selective A3 adenosine receptor agonists. Bioorg. Med. Chem. (1995) 3:1331–1343.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B, INFANTAS MJ et al.: Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2- (ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. Med. Chem (1998) 41:3174–3185.
   Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B, SPALLUTO G et al.: Novel N6-(substituted-phenylcarbamoyOadenosine-5'-uronamides as potent agonists for A3 adenosine receptors.' Med. Chem. (1996) 39:802–806.
   Web of Science ®Google Scholar
• KNUTSEN US, SHEARD OWN MJ, ROBERTS SM et al.: Adenosine A1 and A3 selective N-alkoxypurines as novel cytokine modulators and neuroprotectants. Drug Dev. Res. (1998) 45:214–221.
   Web of Science ®Google Scholar
• MOGENSEN JP, ROBERTS SM, BOWLER AN et al: The synthesis of new adenosine A3 selective ligands containing bioisosteric isoxazoles. Bioorg. Med. Chem. Lett (1998) 8:1767–1770.
   PubMed Web of Science ®Google Scholar
• VOLPINI R, COSTANZI S, LAMBERTUCCI C et al: Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists. Carr. Pharm. Des. (2002) 8:2285–2298.
   PubMed Web of Science ®Google Scholar
• VOLPINI R, CAMAIONI E, CONSTANZI S et al.: Synthesis of di- and tri-substituted adenosine derivatives and their affinities at human adenosine receptor subtypes. Nucleosides Nucleotides (1999) 18:2511–2520.
   PubMed Web of Science ®Google Scholar
• KLOTZ KN, CAMAIONI E, VOLPINI R et al.: 2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists, at human A3 adenosine receptors. Naunyn Schmiedeberg's Arch. Pharmacol (1999) 360:103–108.
   Google Scholar
• VOLPINI R, CONSTANZI S, LAMBERTUCCI C et al.: Synthetic procedure for the preparation of novel potent and selective A3 adenosine receptor radioligands. Nucleosides Nucleotides Nucleic Acids (2001) 20:775–779.
   PubMed Web of Science ®Google Scholar
• DENINNO MP, MASAMUNE H, CHENARD LK et al: 3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. Med. Chem. (2003) 46:353–355.
   Web of Science ®Google Scholar
• TRACEY WR, MAGEE WP, OLEYNEKE et al.: Novel N6 substituted adenosine 5'-N-methyl uronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am. J Physiol Heart Circ. Physiol. (2003) (In Press).
   Google Scholar
• GAO Z, KIM S, BIADATTI T et al: Structural determination of A3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. Med. Chem. (2002) 45:4471–4484.
   Web of Science ®Google Scholar
• LEE K, RAVI G, JI X et al: Ring-constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modification. Bioorg. Med. Chem. Lett. (2001) 11:1333–1337.
   PubMed Web of Science ®Google Scholar
• JEONG LS, JIN DZ; KIM HO et al: N6-Substituted D-4'-thioadenosine-5-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. Med. Chem. (2003) 46:3775–3777.
   Web of Science ®Google Scholar
• LIANG BT, JACOBSON KA: A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. USA (1998) 95:6995–6999.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, MORO S, KIM Y et al: Adenosine receptors: protective versus damaging effects identified using novel agonists and antagonists. Drug. Dev. Res. (1998) 45:113–124.
   PubMed Web of Science ®Google Scholar
• PARK KS, HOFFMANN C, KIM HO et al.: Activation and desensitization of rat A3-adenosine receptors by selective adenosine derivatives and xanthine-7-ribosides. Drug Dev. Res (1998) 44:97–190.
   PubMed Web of Science ®Google Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, IJZERMAN AP et al.: The adenosine A3 receptor and its ligands. Frog. Med. Chem. (2001) 38:61–113.
   PubMedGoogle Scholar
• VAN TILBURG EW, VON FRIJTAG DRABBE KONZEL J, DE GROOTE M et al: 2,5'-Disubstituted adenosine derivatives: Evaluation of selectivity and efficacy for the adenosine A1, A2A and A3 receptor. j. Med. Chem. (2002) 45:420–429.
   PubMed Web of Science ®Google Scholar
• AUCHAMPACH JA, GE ZD, WAN TC et al.: A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia reperfusion injury in dogs. Am. I Physiol Heart Circ. Physiol (2003) 285:H607–H613.
   PubMed Web of Science ®Google Scholar
• SAFRAN N, SHNEYVAYSV, BALAS N et al.: Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell. Biochem. (2001) 217:143–152.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S: Pharmacology and therapeutic applications of A3 receptor subtype. Curl: Top. Med. Chem. (2003) 3:463–469.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review by experts in the field.
   Google Scholar
• BAR-YEHUDA S, MADI L, BARAK D et al.: Agonists to the A3 adenosine receptor induce G-CSF production via NFkappaB activation: a new class of myeloprotective agents. Exp. Hematol (2002) 30:1390–1398.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, MADI L: A3 adenosine receptor as a target for cancer therapy. Anti-Cancer Drugs (2002) 13:437–443.
   PubMed Web of Science ®Google Scholar
• BALDWIN SA, BEAU PR, YAO SY et al: The equilibrative nucleoside transporter family, 5LC29. Pflirgers Arch. (2003) (In Press).
   Google Scholar
• GRAY JH, OWEN RP, GIACOMINI KM: The concentrative nucleoside transporter family, 5LC28. Pflirgers Arch. (2003) an Press).
   Google Scholar
• SAWCHUK RJ, YANG Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv. Drug Deify. Rev (1999) 39:5–31.
   PubMed Web of Science ®Google Scholar
• DUNWIDDIE TV, MASINO SA: The role and regulation of adenosine in the central nervous system. Ann. Rev. Neurosci. (2001) 24:31–55.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, NIKODIJEVIC O, SHI D et al.: A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. (1993) 336:57–60.
   PubMed Web of Science ®Google Scholar
• PETERS DM, GIES EK, GELB CR, PETERFREUND RA: Agonist-induced desensitization of A2B adenosine receptors. Biochem. Pharmacol (1998) 55:873–882.
   PubMed Web of Science ®Google Scholar
• CIRUELA F, SAURA C, CANELA El et al.: Ligand-induced phosphorylation, clustering, and desensitization of A1 adenosine receptors. Ma Pharmacol (1997) 52:788–797.
   PubMed Web of Science ®Google Scholar
• SAURA CA, MALLOL J, CANELA El et al.: Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization. Biol. Chem. (1998) 273:17610–17617.
   Web of Science ®Google Scholar
• WETHERINGTON JVV, LAMBERT NA: Differential desensitization of responses mediated by presynaptic and postsynaptic A1 adenosine receptors. Neurosci. (2002) 22:1248–1255.
   PubMed Web of Science ®Google Scholar
• CONTI A, LOZZA G, MONOPOLI A: Prolonged exposure to 5'-N-ethylcarboxamidoadenosine (NECA) does not affect the adenosine A2A-mediated vasodilation in porcine coronary arteries. Pharmacol Res. (1997) 35: 123–128.
   Google Scholar
• CHERN Y, LAI HL, FONG JC et al: Multiple mechanisms for desensitization of A2A adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Ma Pharmacol (1993) 44:950–958.
   PubMed Web of Science ®Google Scholar
• PALMER TM, GETTYS TW, JACOBSON KA et al: Desensitization of the canine AL adenosine receptor: delineation of multiple processes. MM. Pharmacol (1994) 45:1082–1094.
   PubMed Web of Science ®Google Scholar
• MATHARU AL, MUNDELL SJ, BENOVIC JL et al.: Rapid agonist-induced desensitization and internalization of the A2B adenosine receptor is mediated by a serine residue close to the COOH terminus. Biol. Chem. (2001) 276:30199–30207.
   Web of Science ®Google Scholar
• TRINCAVELLI ML, TUSCANO D, CECCHETTI P et al.: Agonist-induced internalization and recycling of the human A(3) adenosine receptors: role in receptor desensitization and resensitization. Neurochem. (2000) 75:1493–1501.
   PubMed Web of Science ®Google Scholar
• STAMBAUGH K, JACOBSON KA, JIANG JL et al.: A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged stimulated ischemia. Am.' Physiol (1997) 273:H501–H505.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M, KOWALUK EA, ARNERIC SP: Emerging molecular approaches to pain therapy. Med. Chem. (1999) 42:1481–1500.
   Web of Science ®Google Scholar
• OKUSA MD, LINDEN J, MACDONALD T et al.: Selective A2A adenosine receptor activation reduce ischemia-reperfusion injury in rat kidney. Am. J. Physiol Rena] Physiol (1999) 277:F404–F412.
   PubMed Web of Science ®Google Scholar
• DIXON, DA, FENIX LA, KIM DM et al: Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann. Pharmacother (1999) 33:480–488.
   PubMed Web of Science ®Google Scholar
• VIZIANO M, ONGINI W, CONTI A et al: 2-[N'-(3-Arylallylidene)hydrazino]adenosines showing A2A adenosine agonist properties and vasodilation activity. j. Med. Chem (1995) 38:3581–3585.
   PubMed Web of Science ®Google Scholar
• CASATI C, MONOPOLI A, DIONISOTTI S et al.: Repeated administration of selective adenosine A1 and A2 receptor agonists in the spontaneously hypertensive rat: tolerance develops to Al-mediated hemodynamic effects. Pharmcol Exp. Ther (1994) 268:1506–1511.
   PubMed Web of Science ®Google Scholar
• BELARDINELLI L, LU J, DENNIS D et al.: The cardiac effects of a novel Al-adenosine receptor agonist in guinea pig isolated heart. Pharmacol Exp. Ther. (1994) 271:1371–1382.
   PubMed Web of Science ®Google Scholar
• VAN SCHAICK EA, KULKARNI, C, VON FRIJTAG DRABBE KONZEL JK et al.: Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: Comparison of pharmacokinetic, hemodynamic and EEG effects. Naunyn-Schmiedeberg's Arch. Pharmacol (1997) 356:827–837.
   Google Scholar
• WAGNER H, MILAVEC-KRIZMAN M, GADIENT F et al.: General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine A1 receptor agonist. Drug Dev. Res. (1995) 34:276–288.
   Web of Science ®Google Scholar
• SAWYNOK J: Adenosine receptor activation and nociception. Ear: J Pharmacol (1998) 347:1–11.
   PubMed Web of Science ®Google Scholar
• VON LUBITZ DKJE, LIN RCS, POPIK P et al.: Adenosine A3 receptor stimulation and cerebral ischemia. Ear: Pharmacol (1994) 263:59–67.
   PubMed Web of Science ®Google Scholar
• LONDOS C, HONNER RC, DHILLON GS: cAMP dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase..1. Biol. Chem. (1980) 260:15139–15145
   Google Scholar
• SALORANTA C, FRANSILLA-KALLUNKI A, EKSTRAND A et al.: Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia (1991) 34:409–415.
   PubMed Web of Science ®Google Scholar
• BAI TR, WEIR T, WALKER BAM et al.: Comparison and localization of adenosine A3 receptor expression in normal and asthmatic lung. Drug Dev. Res. (1994) 31:244.
   Google Scholar
• SAJJADI FG, TAKABAYASHI K, FOSTER AC et al.: Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. Immunology (1996) 156:3435–3442.
   Web of Science ®Google Scholar
• GONGOR T, MALABRE P, TEULON JM et al.: N6-Substituted adenosine receptor agonists. Synthesis and pharmacological activity as potent antinociceptive agents. Med. Chem. (1994) 37:4307–4316.
   Web of Science ®Google Scholar
• HANDFORTH A, TREIMAN DM: Effect of an adenosine antagonist and an adenosine agonist on status entry and severity in a model of limbic status epilepticus. Epilepsy Res. (1994) 18:29–42.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, KIM HS, RAVI G et al: Engineering of A3 adenosine and P2Y nucleotide receptors and their ligands. Drug Dev. Res. (2003) 58:330–339.
   PubMed Web of Science ®Google Scholar
• GAO Z-G, VAN MUIJLWIJK-KOEZEN JE, CHEN A et al: Allosteric modulation of A3 adenosine receptors by a series of 342-pyridinyl)isoquinoline derivatives. MM. Pharmacol (2001) 60: 1057–1063.
   Google Scholar
• GAO Z-G, KIM SG, SOLTYSIAK KA et al.: Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. MM. Pharmacol (2002) 62:81–89.
   PubMed Web of Science ®Google Scholar
• GAO ZG, MELMAN N, ERDMANN A et al.: Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at Al and A3 adenosine receptors. Biochem. Pharmacol (2003) 65:525–534.
   PubMed Web of Science ®Google Scholar
• GAO Z-G, KIM S-K, GROSS AS et al: Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor. Ma Pharmacol (2003) 63:1021–1031.
   PubMed Web of Science ®Google Scholar
• CHENG J, BEARD J: DTI0009, a novel selective A1 agonist, suppresses AV nodal conduction without hypotensive effect. Circulation (2002) 106:545.
   Google Scholar
• ZAZA A: CVT-510 (CV Therapeutics). CLIFF. Opin. Investig. Drugs (2002) 3:96–100.
   PubMedGoogle Scholar
• LERMAN BB, ELLENBOGEN KA, KADISH A: Electrophysiological effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. Cardiovasc. Pharmacol Ther. (2001) 6:237–245.
   PubMedGoogle Scholar
• PRYSTOWSKY EN, NIAZI I, CURTIS AB: Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel Al-adenosine receptor agonist. ./. Am. Coll. Cardiol (2003) 42:1098–1102.
   PubMed Web of Science ®Google Scholar
• LASLEY RD, NARAYAN P, JAHANIA MS et al.: Species-dependent hemodynamic effects of adenosine A3-receptor agonists IB-MECA and CI-IB-MECA. Am. .1. Physiol (1999) 276:H2076–H2084.
   Google Scholar
• KILPATRICK EL, NARAYAN P, MENTZER RIVI JR: Adenosine A3 agonist cardioprotection in isolated rat and rabbit heart blocked by the A1 antagonist DPCPX. Am.Physiol Heart Circ. Physic] (2001)281:H847–H853.
   PubMed Web of Science ®Google Scholar